24 medicines in J-K declared "sub-standard"

Image
Press Trust of India Srinagar
Last Updated : Aug 03 2013 | 5:30 PM IST
As many as 24 medicines currently available in the hospitals and chemist shops across Jammu and Kashmir have been declared as "sub-standard" by two premier drug testing laboratories of the country.
Central Drugs Laboratory, Kolkata and Regional Drugs Testing Laboratory, Chandigarh had analysed 156 samples drawn by drug inspectors of Central Drugs Standard Control Organisation (CDSCO) from different locations in the state in connection with the supply of spurious drugs in the government-run hospitals.
An official in the Drug Controller Department Jammu said the department has taken action after the report came and various drugs have been seized, even as the inquiry is on.
"We have seized certain medicines after the report by the two laboratories reached us and we have also sent show cause notices to various manufacturing companies in this regard. We are duty-bound to act against spurious drugs," he said.
In their report to CDSCO, the laboratories have listed 24 medicines, including two taken from the premier healthcare institute in the Valley - SKIMS, as sub-standard.
The laboratories found the samples of Injection Amoxicillin and Potassium Clavulenate taken from SKIMS and manufactured by a Karnataka based company as sub-standard and having the presence of particulate matter, the report said.
Similarly, the analysis of another drug from the same institute, Injection Zepoxin, manufactured by a Mumbai based company, showed no clarity of the solution and presence of particulate matter, it said.
The samples were taken randomly from various hospitals in Pulwama, Pampore, Baramulla, Doda, Bhaderwah and Srinagar.
The samples of the drug Clonazepam 1 mg taken from the Valley's only psychiatric hospital here also turned out to be sub-standard, the report mentions.
The laboratories also found that spurious drugs were being sold in chemist shops across the state, as many samples, taken from such shops in Pulwama, Udhampur, Srinagar and Kishtwar were found to be sub-standard.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 03 2013 | 5:30 PM IST

Next Story